Logo

Regeneron & Sanofi Report P-III Trial Results of Dupixent (dupilumab) for Eosinophilic Esophagitis in Children Aged 1 to 11 Years

Share this
Regeneron & Sanofi Report P-III Trial Results of Dupixent (dupilumab) for Eosinophilic Esophagitis in Children Aged 1 to 11 Years

Regeneron & Sanofi Report P-III Trial Results of Dupixent (dupilumab) for Eosinophilic Esophagitis in Children Aged 1 to 11 Years

Shots:

  • The P-III trial evaluates Dupixent (high/low dose) vs PBO in 102 children aged 1 to 11yrs. with EoE
  • The trial met its 1EPs of histological disease remission @16wks., 68% & 58% of children in a high & low dose. In high dose, 86% vs 21% reduction in peak esophageal intraepithelial eosinophil count from baseline; 0.88 & 0.84 vs 0.02 & 0.05 in disease severity & extent; 3.5 vs 0.3 point in abnormal endoscopic, improvement in the proportion of days & children experienced symptoms of EoE but not statistically significant
  • The lower dose group's 2EPs were equivalent to the higher dose. The safety results were consistent with the safety profile of Dupixent in children & adults aged ≥12yrs., AEs (79% vs 91%) & treatment discontinuation due to AEs (0% vs 6%) @16wk.

Ref: PRNewswire | Image: Sanofi

Click here to­ read the full press release 

Neha

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions